Adriana De Siervi
Transcripción
Adriana De Siervi
Adriana De Siervi Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, Instituto de Biología y Medicina Experimental (IBYME) - CONICET http://www.ibyme.org.ar/laboratorios/44/oncologia-molecular-y-nuevos-blancosterapeuticos Vuelta de Obligado 2790, 1428ADN - Capital Federal - Argentina E-mail: [email protected] Phone: +5411-4783-2869 ext. 206 y Mobil: 15-3269-5832 Present Position Independent Investigator (CONICET) Lab chief at Laboratory of Molecular Oncology and New Therapeutic Targets – Instituto de Biología y Medicina Experimental (IBYME) Buenos Aires, Argentina. Education 1993 M.S. Biology (FCEN-UBA). 1998 Ph.D. in Molecular Biology (FCEN-UBA). Doctoral thesis: “Molecular genetic of the Acute Intermittent Porphyria: First study in the Argentinean population”. Mentor: Prof. Dra. María Victoria Rossetti. 2001-2006 Postdoct at National Institutes of Health (NIH – USA). Research positions and employment 1994-1998 Ph.D. student: Porphyrins and Porphyrias Research Center (CIPYP). CONICET, School of Sciences (FCEyN), University of Buenos Aires (UBA). Argentina. Initiation and improvement fellowships (CONICET). 1996 Invited Scientist: Department of Human Genetic, Mount Sinai Medical School, New York, USA. “Detection, identification and expression of mutations in Argentinean patients with Acute Intermittent Porphyria”. Mentor: Dr. Robert Desnick. 1998-2001 Post-doctoral fellowship from CONICET at the CIPYP, FCEN, UBA, Argentina. “Molecular genetics of Acute Porphyrias. Studies about the association with hepatocellular cáncer”. Mentor: Prof. Dr. Alcira Batlle. 2001-2003 Postdoctoral fellowship from Fogarty at the Oral and Pharyngeal Cancer Branch (OPCB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), USA. “Mechanism of action of chemotherapy drugs:CDK inhibitors”. Mentor: Dr. Adrián Senderowicz. 2003-2006 Postdoctoral fellowship from Fogarty at the Laboratory of Receptor Biology & Gene Expression, National Cancer Institute (NCI), NIH, USA. “Transcription and cancer”. Mentor: Dr. Kevin Gardner. Curriculum vitae Adriana De Siervi 2016 1 2006 2007-2012 Re-insertion fellowship from CONICET until obtains investigator position at the same Council, Laboratory of Apoptosis and Cancer, Department of Biological Chemistry, School of Sciences (FCEyN), University of Buenos Aires (UBA). Argentina. Associate Investigator from the CONICET, Laboratory of Apoptosis and Cancer, Department of Biological Chemistry, School of Sciences (FCEyN), University of Buenos Aires (UBA). Argentina. 2012-2013 Independent Investigator from the CONICET, Laboratory of Apoptosis and Cancer, Department of Biological Chemistry, School of Sciences (FCEyN), University of Buenos Aires (UBA). Argentina. 2013-present Independent Investigator (CONICET) Head of the Laboratory of Molecular Oncology and New Therapeutic Targets – Institute of Biology and Experimental Medicine (IBYME) Buenos Aires, Argentina. Honors 2002. NIDCR Award: NIH (USA), in recognition of outstanding achievements in oral health and craniofacial research. 2008. Irene Faryna Award (Mar del Plata, Argentina) for the best scientific work in oncology field: Gueron, G; Ferrando, M; Salierno, M; De Luca, P; De Siervi, A; Vazquez, E. “Rol crítico de la expresión de hemo oxigenasa 1 (HO-1) como un modulador del potencial invasivo de células de cáncer de próstata”. 2009. AACR award (USA): Prostate Cancer Foundation– Prostate Cancer recognition award presented to promising young cancer researchers who are the first authors and of highly rated proffered papers focused on advance/late prostate cancer research, American Association 100th Annual Meeting 2009: “Critical role of endogenous heme oxygenase 1 (HO-1) as a turner of the invasive potential of prostate cancer in vitro and in vivo through MMP9 modulation”. G. Gueron, M. Ferrando, M. Salierno, P. De Luca, B. Elguero, R. Meiss, A. De Siervi, N. Navone, E. Vazquez. 2010. AACR-AstraZeneca International Scholar-in-Training Award, American Association 101st Annual Meeting 2010: “Nuclear translocation of HO-1 in Prostate cancer. Role beyond heme degradation”. G. Gueron, M. Ferrando, B. Elguero, A. Salles, R. Meiss, L. Colombo, A. Curino, MM. Facchinetti, N. Navone, A. De Siervi, E. Vazquez. 2012. Award: ATM transcriptional regulation mediated by BRCA1/E2F1 axis controls DNA damage response in prostate cancer. Authors: Moiola C, De Luca P, Zalazar F, Cotignola J, Gardner K, Vazquez E, De Siervi A. Selected abstract from the top 5% best posters presented at 103rd Annual Meeting American Curriculum vitae Adriana De Siervi 2016 2 Association for Cancer Research AACR (Chicago, USA, March 31st to April 4th 2012). Proc. AACR (2012) 53: p.270. Abstract: 1312 (poster). 2013. Award MONTOURI-FUNDACION GADOR at oncology field: CtBP1 is a molecular metabolic switch that mediates prostate tumor development dependent of high-fat diet. Authors: Moiola C, De Luca P, Zalazar F, Cotignola J, Meiss R, Vallecorsa P, Mazza O, Scorticati C, Paz D, Pignataro O, Vazquez E, De Siervi A. LVIII Reunión Científica Anual de la SAIC (Mar del Plata, Buenos Aires, Argentina) November 20th – 23rd 2013. Medicina. Amount: U$2.000. Grants PICT 2015 (1345) Plan Argentina Innovadora 2020: Molecular studies that associates metabolic syndrome and breast and prostate cancer development. Amount: U$90.000. Ongoing. PICT 2014 (324) Plan Argentina Innovadora 2020: MicroRNAs: new molecular tools for early diagnosis and therapy against cancer in a metabolic syndrome animal model. Amount: U$60.000. Ongoing. PICT 2012 (374), PI: Molecular studies that associates hipercaloric diet and breast and prostate tumor development. Amount: $70.000. Ongoing. Financial assistance to cancer projects from National Cancer Institute (Argentina) 2012-2014: Molecular studies that associates obesity and breast and prostate cancer risks. Amount: U$40.000. Ongoing. PICT RAICES 2010-2013 (431), Co-PI: Nuclear localization of Heme Oxygenase 1 (HO1) in prostate cancer: a function beyond heme degradation. PI Dr. Elba Vazquez. Amount: U$90,000. Expired. PICT RAICES 2006-2009 (367), Co-PI: HO1 and VEGF role in bone metastasis from prostate cancer. PI Dr. Elba Vazquez. Amount: U$90,000. Expired. UBACYT (X230), Co-investigator: HO1 and VEGF role in bone metastasis from prostate cancer. PI Dr. Elba Vazquez. Amount: U$20,000. Expired. PICT 2006-2009 (228), PI: BRCA1 role in prostate cancer. Amount: U$90,000. Expired. Research in Molecular Biology and proteomics grant from ORT school (2007). Amount: U$1,000. Expired. Mentor of undergraduate students: 1. Débora Weiss Cádiz (03/1999 - 03/2000) FCEN, UBA, Argentina. 2. Carolina Rezaval (03/2000 - 10/2000) FCEN, UBA, Argentina. 3. Terence Sy (08/2001 - 08/2002) NIDCR, NIH, USA. 4. Doreen Toskos (06/2002 - 09/2002) NIDCR, NIH, USA. 5. Carol Hwang (03/2002 - 03/2003) NIDCR, NIH, USA. 6. Violet Fernandez (03/2003 - 11/2003) NIDCR, NIH, USA. Curriculum vitae Adriana De Siervi 2016 3 7. Andrea Graham (06/2003 - 11/2003) NIDCR, NIH, USA. Mentor of undergraduate thesis 1. Marina Ruiz Grecco (14/3/2008) FCEN, UBA. Director. Qualification: 10. 2. Mercedes Ferrando (20/3/2008) FCEN, UBA. Co-director. Qualification: 10. 3. Julián Chamorro (11/2008) FCEN, UBA. Director. Qualification: 10. 4. Florencia Zalazar (18/3/2009) FCEN, UBA. Director. Qualification: 10. 5. Federico Aranda (14/4/2009) FCEN, UBA. Co-director. Qualification:10. 6. Estefanía Labanca (11/4/2014) FCEN, UBA. Director. Qualification: 10. 7. Nicolás Dalton (19/12/2013) FCEN, UBA. Director. Qualification: 10. Mentor of doctoral thesis: 1. Paola De Luca (1/04/07 - 29/12/11) FCEN, UBA. Director. Qualification: Oustanding. 2. Cristian Moiola (1/7/2008 - 18/03/2013) FCEN, UBA. Director. Qualification: Oustanding. 3. Belén Elguero (1/10/2008 - 28/05/2013) FCEN, UBA. Director. Qualification: Oustanding. 4. Florencia Zalazar (1/4/09 - 11/05/2015) FCEN, UBA. Director. Qualification: Oustanding. 5. Nicolás Dalton (1/5/2014 – ongoing) IBYME – CONICET. 6. Cintia Massillo (1/6/2014 – ongoing) IBYME – CONICET. 7. Juliana Porretti (1/7/2014 – ongoing) IBYME – CONICET. Mentor of post-doctoral fellowship: Paola De Luca (1/4/2012- 30/9/2014) Postdoctoral fellow CONICET. FCEN, UBA; IBYME. Cristian Moiola (1/4/2013- 1/02/2015) Postdoctoral fellow CONICET. FCEN, UBA; IBYME. Mentor of investigators Javier Cotignola (11/2009 – 11/2015) Co-director, assistant investigator CONICET. FCEN – UBA. Paola De Luca (1/10/2014- ongoing) Director, assistant investigator CONICET. IBYME. Mentor of masters Maria Luz Pujol (1/2/2014 - 30/9/2014) Microfluidic and Biological Engineering, Department of Microsystems Engineering–IMTEK, Centre for Biological Signalling Studies-BIOSS (University of Freiburg, Germany). Codirector. Mentor of doctoral fellowship Paola De Luca, director CONICET type I and II fellow from 1/04/07 to 31/3/2012 Departamento de Química Biológica, FCEN – UBA. Cristian Moiola, director CONICET type I and II fellow from 1/7/08 to 31/3/13 Departamento de Química Biológica, FCEN – UBA. Mercedes Ferrando, co-director CONICET type I and II fellow from 1/04/08 to 31/3/2012 Departamento de Química Biológica, FCEN – UBA. Director: Dra. Elba Vazquez. Curriculum vitae Adriana De Siervi 2016 4 Belén Elguero, co-director CONICET type I and II fellow from 1/10/08 to 31/3/2013 Departamento de Química Biológica, FCEN – UBA. Director: Dra. Elba Vazquez. Florencia Zalazar, director CONICET type I and II fellow from 1/04/09 to 31/3/2014 Departamento de Química Biológica, FCEN – UBA. Nicolás Dalton, director ANPYCT fellowship from 1/5/14 Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME, CONICET). Ongoing. Cintia Massillo, director CONICET fellowship from 1/6/14 Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME, CONICET). Ongoing. Juliana Porretti, director CONICET fellowship from 1/6/14 Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME, CONICET). Ongoing. Georgina Daniela Scalise director INC fellowship from 1/8/16 Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME, CONICET). Ongoing. Member of review committee Reviewed 11 Doctoral Thesis, Universidad de Buenos Aires, Argentina. Reviewed 10 Undergraduate Thesis, Universidad de Buenos Aires, Argentina. Reviewed 2 Master Thesis, Universidad de Buenos Aires, Argentina. Professional memberships and reviewer 2008-present: Active member of the American Association for Cancer Research (AACR), USA. 2008-present: Active member of the Argentinean Society of Clinical Investigation (SAIC), Argentina. 2009-present: Reviewer of several argentinean grant applications for the National Agency of Science and Technology (ANPYCT), Argentina. 2011: Coordinator of poster session at the meeting of Sociedad Argentina de Investigación Clínica (SAIC), Argentina. 2011: Reviewer (Holland). of one grant application from Dutch Cancer Society 2011-present: reviewer of manuscripts to be consider at: Cancer Research (AACR), Cellular Physiology and Biochemistry (Ed KARGER), Cell Cycle (Ed Landes Bioscience), Frontiers in Bioscience (Ed Landmark), Frontiers in Oncology (Ed Nature Publishing Group), Tumor Biology (Ed Springer), Journal of Investigative Dermatology (Ed Nature Publishing Group), Oncogene (Ed Nature Publishing Group), Asian Journal of Andrology (Ed Asian Society of Andrology), Tumori (Istituto Nazionale dei Tumori), PLOS one (PLOS), JAMA Oncology (Ed JAMA), Molecular Cancer Therapeutics (Ed AACR), Journal of Translational Medicine (Ed BioMed central), Cancer Curriculum vitae Adriana De Siervi 2016 5 Biology and Medicine (Ed Chinese Anticancer Association), Oncotarget (Editorial Impact Journal). 2012-present: Reviewer for investigator promotions from CONICET, Argentina. 2012-present: Reviewer of one grant for National Agency Research from Uruguay (ANII) Fondo María Viñas 2011 (FMV 2011). 2012-present: Managing Editor from Frontiers in Bioscience (Landmark). 2013-present: Review Editor from Frontiers in Oncology, Ed. Nature Publishing Group. Teaching 1995. Teaching assistant for undergraduate Medicine, University of Buenos Aires. student course, School of 1996-1998. Graduate Teaching Assistant for graduate student course: Molecular diagnosis in medicine. National Research Institute on Porphyrins and Porphyrias (CIPYP), School of Sciences, University of Buenos Aires. 2006-present. Presentation of one lecture: “Transcription factors with oncogenic properties” at the graduate students course: “Apoptosis and cancer: molecular and cellular basis” , Dr. Elba Vazquez, FCEN, University of Buenos Aires. 2008-present. Presentation of two lectures: “Transcription factors and cancer” “MiRNAs in cancer: from básic to clinical research” at the graduate students course: “Carcinogenesis”, Dr. Claudia Lanari, IBYME, CONICET. 2010-present. Organization of seminar series of the Department of Biological Chemistry, FCEN, UBA, together with Dr. Cybele Garcia. Lecture presentations Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, USA. “Transcriptional activation of p21WAF1 by Perifosine”. March 2003. Laboratory of Biology Receptor and Gene Expression, National Cancer Institute, NIH, USA. “Transcriptional activation of p21WAF1 by Perifosine”. November 2003. Genitourinary Medical Oncology Seminar series, M D Anderson, Houston, Texas, USA. “Transcriptional activation of p21WAF1 by Perifosine”. March 2005. Laboratory of Biology Receptor and Gene Expression, National Cancer Institute, NIH, USA. “BRCA1 assembles a repressive protein complex at its own promoter”. March 2006. American Association for Cancer Research (AACR) San Diego, CA, USA. BRCA1 regulates GADD153-mediated apoptosis in prostate cancer cells. April 2008. Curriculum vitae Adriana De Siervi 2016 6 Seminar series of the Department of Biological Chemistry, FCEyN – UBA. “BRCA1 role in the regulation of transcription.” June 2008. Seminar series of the IIB – University of San Martin (UNSAM). “Studies about cell cycle regulators, tumor suppressors and oncogenes involve in progression and prostate cancer therapy.” April 2011. Seminar series IBYME. Molecular studies that associates obesity with breast and prostate cancer risk. May 2012. Publications 1. Leonardi DB, Abbate M, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapse. Oncotarget. 2016 doi: 10.18632/oncotarget.8606. In press. 2. De Luca P, Dalton GN, Scalise GD, Moiola CP, Porretti J, Massillo C, Kordon E, Gardner K, Zalazar F, Flumian C, Todaro L, Vazquez ES, Meiss R, De Siervi A. CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs. Oncotarget. 2016. 7(14):18798-811. 3. De Luca P, De Siervi A. Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis. Frontiers in Bioscience. 2016. 8:72-83. 4. Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone N, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer Res. 2015. 13(11):1455-64. Highlighted in the issue of the journal. 5. Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R; Spallanzani RG; Vallecorsa P; Elguero B; Cotignola J; Vazquez E & De Siervi A. Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. Curr Pharm Biotechnol. 2015. 16(6):553-63. 6. Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodriguez-Segui S, Gardner K, Meiss R, Vallecorsa P, Pignataro O, Mazza O, Vazquez ES, De Siervi A. Prostate tumor growth is impaired by CtBP1 depletion in high fat diet fed mice. Clinical Cancer Research. 2014. 20(15):4086-95. 7. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. Heme Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulates the Oxidative Response in Bone Cells. PLoS One. 2013;8(11):e80315. 8. De Luca P, Moiola C, Zalazar F, Gardner K, Vazquez E & De Siervi A. BRCA1 and p53 regulate critical prostate cancer pathways. Prostate Cancer and Prostatic Diseases. 16(3):233-8. (2013) 9. Palm T, Hemmer K, Winter J, Fricke I, Tarbashevich K, Sadeghi Shakib F, Rudolph IM, Hillje AL, De Luca P, Bahnassawy L, Madel R, Viel T, De Siervi A, Jacobs A, Diederichs S, Schwamborn J. A systemic transcriptome analysis reveals the regulation of neural stem cell maintenance by an E2F1-miRNA feedback loop. Nucleic Acids Research. 41(6):3699-3712 (2013). Curriculum vitae Adriana De Siervi 2016 7 10. Cotignola J, Leonardi D, Shahabi A, Acuña A, Stern M, Navone N, Scorticati C, De Siervi A, Mazza O & Vazquez E. Glutathione-S-Transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer & Prostatic Diseases. 16(1):28-34. (2013). 11. Elguero B, Gueron G, Giudice J, Toscani M, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone N, De Siervi A & Vazquez E. Unveiling the Association of STAT3 and HO-1 in Prostate Cancer : Role beyond Heme Degradation. Neoplasia. 14(11):104356. (2012). 12. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E & De Siervi A. Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cellular Physiology and Biochemistry. 30(3):596-608. (2012). 13. Gueron G, De Siervi A, Vazquez E. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer & Prostatic Diseases. 15(3):213-21 (2012). 14. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. 14(4):467-479 (2011). 15. De Luca P, Vazquez E, Moiola C, Zalazar F, Cotignola J, Gueron G, Gardner K & De Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol. Cancer Res. 9(8):1078-90 (2011). 16. Gueron G, De Siervi A & Vazquez E. Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications. Curr Pharm Biotechnol. 12: 186780 (2011). Invitación para escribir un review. 17. Di LJ, Fernandez AG, De Siervi A, Longo D & Gardner K. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat. Struct. & Mol. Biol. 17: 1406–1413 (2010). Highlighted at NCI, NIH-USA web site: http://www.cancer.gov/newscenter/pressreleases/BRCA1proteinobesity Highlighted in the journal http://www.nature.com/nsmb/journal/v17/n12/index.html#rhighlts 18. Moiola C, De Luca P, Gardner K, Vazquez E & De Siervi A. Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell cycle. 9(15):3119-26 (2010). 19. De Siervi A, De Luca P, Byun JS, Di LJ, Fufa T, Haggerty CM, Vazquez E, Moiola C, Longo DL, Gardner K. Transcriptional autoregulation by BRCA1. Cancer Res. 70(2):532-42 (2010). 20. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res. 7(11):1745-55 (2009). 21. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke S, Haggerty CM, Player A, Wang YH, Thirman MJ, Kaberlein JJ, Petrovas C, Koup RA, Longo D, Ozato K, Gardner K. Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes. Proc Natl Acad Sci USA. 106(46):19286-91 (2009). 22. De Siervi A, De Luca P, Moiola C, Gueron G, Tongbai R, Chandramouli GV, Haggerty C, Dzekunova I, Petersen D, Kawasaki E, Kil WJ, Camphausen K, Longo D, Gardner K. Curriculum vitae Adriana De Siervi 2016 8 Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis. Cell Cycle. 8(13):2093-100 (2009). 23. Macias E, Miliani de Marval PL, De Siervi A, Conti CJ, Senderowicz AM, RodriguezPuebla ML. CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development. Am J Pathol. 173(2):526-35 (2008). 24. Ge Y, Byun JS, De Luca P, Gueron G, Li QQ, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, De Siervi A, Gardner K. Combinatorial anti-leukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide CPS49 and flavopiridol. Mol Pharmacol. 74(3):872-83 (2008). 25. Smith J, Freebern WJ, Collins I, De Siervi A, Montano I, Haggerty CM, McNutt MC, Butscher WG, Dzekunova I, Petersen DW, Kawasaki E, Merchant JL, Gardner K. Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc Natl Acad Sci USA. 101(32):11554-11559 (2004). 26. De Siervi A, Marinissen MJ, Diggs J, Wang X-F, Pages Gilles & Senderowicz AM Transcriptional activation of p21waf1/cip1 by alkylphospholipids. Role of the MAPK pathway in the transactivation of the human p21 waf1/cip1 promoter by Sp1. Cancer Res 64:743-750 (2004). 27. Facchinetti MM, De Siervi A, Toskos D & Senderowicz AM UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res. 64(10):3629-3637 (2004). 28. Lahusen T*, De Siervi A*, Kunick C & Senderowicz A. Alsterpaullone, a novel cyclindependent kinase inhibitor, induces apoptosis by activation of caspase 9 due to perturbation in mitochondrial membrane potential. Mol Carcinogenesis. 36(4):183-94 (2003). 29. Parera VE, De Siervi A, Varela L, Rossetti MV, Batlle AM. Acute porphyrias in the Argentinean population: a review. Cell Mol Biol 49(4):493-500 (2003). 30. De Siervi A, Vazquez E, Rezaval C, Rossetti MV & Batlle A. -aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines. BioMed Central cancer 2:6 (2002). 31. De Siervi A, Varela LS, Parera VE, Batlle A & Rossetti MV. Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem. 38: 149-152 (2001). 32. De Siervi A, Parera VE, Batlle A & Rossetti MV. Two new mutations (H106P and L178V) in the protoporphyrinogen oxidase gene in Argentinean patients with variegate porphyria. Human Mutation MPR #181 (on line) (2000). 33. De Siervi A, Weiss Cádiz DE, Parera VE, Batlle A & Rossetti MV. Identification and characterization of two novel mutations that produce Acute Intermittent Porphyria: a 3 base deletion (841-843delGGA) and a missense mutation (T35M). Human Mutation MIB #370 (on line) (2000). 34. Mendez M, Rossetti MV, De Siervi A, Batlle A & Parera VE. Mutations in familial Porphyria Cutanea Tarda: two novel and two previously described for hepatoeritropoietic porphyria. Human Mutation. MIB #354 (on line) (2000). 35. De Siervi A, Parera VE, Varela LS, Batlle A & Rossetti MV. A novel mutation (1320InsT) identified in two Argentine families with Variegate Porphyria. Human Mutation. MPR #140 (on line) (2000). Curriculum vitae Adriana De Siervi 2016 9 36. De Siervi A, Mendez M, Parera VE, Varela LS, Batlle A & Rossetti MV. Acute Intermittent Porphyria: characterization of two novel mutations in the Porphobilinogen deaminase gene, one aminoacid deletion (453-455delAGC) and one splicing aceptor site mutation (IVS8-1G>T). Human Mutation. MIB #271 (on line); 14(4):355 (1999). 37. De Siervi A, Rossetti MV, Parera VE, Mendez M, Varela LS & Batlle A. Acute intermittent porphyria: Biochemical and clinical analysis in the Argentinean population. Clinica Chimica Acta 288:63-71 (1999). 38. De Siervi A, Rossetti MV, Parera VE, Astrin KH, Aizencang GI, Glass IA, Batlle A & Desnick RJ. Identification and characterization of hydroxymethylbylane synthase mutations causing acute intermittent porphyria: Evidence for an ancestral founder of the common G111R mutation. American Journal of Medical Genetics. 86:366-375 (1999). 39. De Siervi A, Rossetti MV, Lezama D & Batlle A. Porphyrin biosynthesis in normal and Haem mutants of S. cerevisiae. Studies about the inheritance of the Hem R + phenotype. Comparative Biochemistry and Physiology. 115B(2):167-173 (1996). International and national meetings She presented more than 150 publications at national and international meetings. Curriculum vitae Adriana De Siervi 2016 10